<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="60387">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01840735</url>
  </required_header>
  <id_info>
    <org_study_id>GS-US-234-0117</org_study_id>
    <nct_id>NCT01840735</nct_id>
  </id_info>
  <brief_title>Phase 1b Safety, Tolerability, and PK Study to Assess GS-5737 in Subjects With CF</brief_title>
  <official_title>A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Single Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of GS-5737 in Subjects With Cystic Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will determine the safety, tolerability, and pharmacokinetics of a single dose of
      GS-5737 administered with a 2.8% saline solution vehicle in adult subjects with CF.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Peak Plasma Concentration (Cmax) of GS-5737</measure>
    <time_frame>1 day</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>GS-5737</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The GS-5737 85 μg dose is contained in 4 mL of 10 mM citrate buffer, pH 5.0 in 2.8% (w/v) saline.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The vehicle control contains 10 mM citrate buffer, pH 5.0 in 2.8% (w/v) saline in 4 mL.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GS-5737</intervention_name>
    <arm_group_label>GS-5737</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males or females, ≥ 18 years of age, at Screening

          -  Diagnosis of CF as determined by the 1997 CF Consensus Conference criteria, with at
             least 1 of the following: Documented sweat chloride ≥ 60 mEq/L by quantitative
             pilocarpine iontophoresis test OR Abnormal nasal transepithelial potential difference
             (NPD) test OR Two well-characterized, disease-causing genetic mutations in the CF
             transmembrane conductance regulator (CFTR) gene AND 1 or more accompanying clinical
             features consistent with CF

          -  FEV1 ≥ 40% and ≤ 90% predicted

          -  BMI ≥ 19 and ≤ 30 kg/m2

          -  Clinically stable with no evidence of significant new or acute respiratory symptoms

          -  Chest radiograph without significant acute findings; or chest radiograph, CT, or MRI
             obtained and interpreted within 90 days prior to enrollment, without acute findings
             and no significant intercurrent illness; chronic, stable findings are allowed

          -  History of lifetime smoking &lt; 5 pack-years (ie, 1 pack per day x 1 year =

             1 pack-year) and non-smokers of at least 60 days duration prior to Screening

          -  Estimated creatinine clearance ≥ 80 mL/min at Screening

          -  Negative drug tests; including alcohol

          -  Hepatitis B, C, &amp; HIV Negative

          -  Surgically sterile or ≥ 12 months post-menopausal

          -  Non-pregnant females

        Exclusion Criteria:

          -  Experienced symptoms of recent acute upper or lower respiratory tract infection or
             acute pulmonary exacerbation requiring treatment within 2 weeks prior to Screening

          -  Plasma potassium ≥ 5 mEq/L

          -  Changes in chronic azithromycin use, bronchodilator (BD), dornase alfa, HS,
             physiotherapy technique or regimen, antibiotics or corticosteroid medications within
             28 days prior to Screening

          -  History of sputum or throat swab culture yielding Burkholderia species within 2 years
             of Screening
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Compass Research Phase 1, LLC</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <lastchanged_date>August 26, 2013</lastchanged_date>
  <firstreceived_date>April 15, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CF</keyword>
  <keyword>Cystic Fibrosis</keyword>
  <keyword>PK</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
